137 related articles for article (PubMed ID: 35114566)
21. Regulation of protein stability by GSK3 mediated phosphorylation.
Xu C; Kim NG; Gumbiner BM
Cell Cycle; 2009 Dec; 8(24):4032-9. PubMed ID: 19923896
[TBL] [Abstract][Full Text] [Related]
22. LZTR1 deficiency exerts high metastatic potential by enhancing sensitivity to EMT induction and controlling KLHL12-mediated collagen secretion.
Abe T; Kanno SI; Niihori T; Terao M; Takada S; Aoki Y
Cell Death Dis; 2023 Aug; 14(8):556. PubMed ID: 37626065
[TBL] [Abstract][Full Text] [Related]
23. Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.
Plotnikov A; Li Y; Tran TH; Tang W; Palazzo JP; Rui H; Fuchs SY
Cancer Res; 2008 Mar; 68(5):1354-61. PubMed ID: 18316598
[TBL] [Abstract][Full Text] [Related]
24. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf.
Cross DA; Alessi DR; Vandenheede JR; McDowell HE; Hundal HS; Cohen P
Biochem J; 1994 Oct; 303 ( Pt 1)(Pt 1):21-6. PubMed ID: 7945242
[TBL] [Abstract][Full Text] [Related]
25. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
26. Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels.
Yang K; Guo Y; Stacey WC; Harwalkar J; Fretthold J; Hitomi M; Stacey DW
BMC Cell Biol; 2006 Aug; 7():33. PubMed ID: 16942622
[TBL] [Abstract][Full Text] [Related]
27. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
[TBL] [Abstract][Full Text] [Related]
28. Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation.
Eom TY; Jope RS
Biol Psychiatry; 2009 Sep; 66(5):494-502. PubMed ID: 19520363
[TBL] [Abstract][Full Text] [Related]
29. 11'-Deoxyverticillin A (C42) promotes autophagy through K-Ras/GSK3 signaling pathway in HCT116 cells.
Niu S; Yuan D; Jiang X; Che Y
Protein Cell; 2014 Dec; 5(12):945-9. PubMed ID: 25261996
[No Abstract] [Full Text] [Related]
30. LZTR1: A promising adaptor of the CUL3 family.
Zhang H; Cao X; Wang J; Li Q; Zhao Y; Jin X
Oncol Lett; 2021 Jul; 22(1):564. PubMed ID: 34113392
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
32. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.
McCubrey JA; Meher AK; Akula SM; Abrams SL; Steelman LS; LaHair MM; Franklin RA; Martelli AM; Ratti S; Cocco L; Barbaro F; Duda P; Gizak A
Aging (Albany NY); 2022 Apr; 14(8):3365-3386. PubMed ID: 35477123
[TBL] [Abstract][Full Text] [Related]
33. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
Koo J; Wu X; Mao Z; Khuri FR; Sun SY
J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
[TBL] [Abstract][Full Text] [Related]
34. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
35. Glycogen synthase kinase 3 regulates expression of nuclear factor-erythroid-2 related transcription factor-1 (Nrf1) and inhibits pro-survival function of Nrf1.
Biswas M; Kwong EK; Park E; Nagra P; Chan JY
Exp Cell Res; 2013 Aug; 319(13):1922-1931. PubMed ID: 23623971
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis.
Gotoh J; Obata M; Yoshie M; Kasai S; Ogawa K
Carcinogenesis; 2003 Mar; 24(3):435-42. PubMed ID: 12663502
[TBL] [Abstract][Full Text] [Related]
37. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
38. Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.
Cirstea IC; Gremer L; Dvorsky R; Zhang SC; Piekorz RP; Zenker M; Ahmadian MR
Hum Mol Genet; 2013 Jan; 22(2):262-70. PubMed ID: 23059812
[TBL] [Abstract][Full Text] [Related]
39. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
Ferro R; Falasca M
World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
[TBL] [Abstract][Full Text] [Related]
40. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
